The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small mole...
Main Authors: | Yanwen Zhong, Xuanyi Li, Hequan Yao, Kejiang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/10/1940 |
Similar Items
-
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
by: Ido Rippin, et al.
Published: (2020-11-01) -
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
by: Natalie Fuchs, et al.
Published: (2024-01-01) -
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01) -
Big peptide drugs in a small molecule world
by: Laszlo Otvos, et al.
Published: (2023-12-01) -
Editorial: Small molecules and peptides in paracrine/autocrine regulation of ovarian folliculogenesis
by: So-Youn Kim, et al.
Published: (2023-03-01)